Two years after it was founded, Padlock acquired by BMS for up to $600mm
Bristol-Myers Squibb Co. acquired autoimmune disease start-up Padlock Therapeutics Inc. for up to $225mm in up-front and near-term contingent milestones. Padlock could also receive $375mm in development and regulatory earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.